Canada DNA Vaccine market is anticipated to grow at a CAGR 41.6% during the forecast period. There are various factors driving the growth of the DNA vaccination market in Canada. This includes increasing healthcare expenditure, investment by cancer research organizations and increasing prevalence of cancer. In May 2017, Canadian Gary kobinger has set to overcome the Zika virus by developing a DNA vaccine. Mice are used in the earlier test of the vaccine. Moreover, the experimental vaccine referred to as GLS-5700, protected all the mice from brain damage, zika infection and death. The vaccine also triggered a robust immune response in the monkeys. The vaccine is also expected to protect the child of pregnant women from Zika infection as well as protect it from microcephaly.